CLIO-ICT

CLIO-ICT is an investigational **MMP-14-activated theranostic nanoparticle** developed for cancer treatment and magnetic-resonance imaging monitoring. It comprises a cross-linked iron oxide nanoparticle core based on ferumoxytol, an MMP-14-cleavable peptide linker, and the vascular-disrupting azademethylcolchicine payload ICT3105. In MMP-14-expressing tumors, linker cleavage releases the tubulin-targeting payload, disrupting tumor endothelium and vasculature and promoting apoptosis of glioblastoma-initiating cells; the iron oxide core enables MRI tracking of tumor delivery. Published mouse studies reported antitumor activity in glioblastoma, including improved outcomes with temozolomide or radiation. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/28659432/))

Other names

ferumoxytol-ICT3105ferumoxytol-ICT-3105ferumoxytol-ICT 3105ICT-CLIO